Products for Research Use Only
RegisterLogin

Troglitazone

CAT: 0804-HY-50935-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-50935-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
CAS Number
97322-87-7
Product Name Alternative
CS-045
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; Ferroptosis; PPAR
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/troglitazone.html
Purity
99.78
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(SC1CC(C=C2)=CC=C2OCC3(C)OC(C(CC3)=C4C)=C(C)C(C)=C4O)NC1=O
Molecular Formula
C24H27NO5S
Molecular Weight
441.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43 (4) :527-50.|[2]Fujita M, et al. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. J Exp Clin Cancer Res. 2017 Jul 3;36 (1) :91.|[3]Nazim UM, et al. PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget. 2017 Apr 18;8 (16) :26819-26831.|[4]Knowler WC, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr;54 (4) :1150-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PPARγ

Alternative Products

CatalogName
T3170-01Troglitazone

Popular Products